AnaptysBio insider Renton Hollings sells shares under 10b5-1 plan

Rhea-AI Filing Summary

Renton Hollings, a director of AnaptysBio (ANAB), exercised options and sold shares under a Rule 10b5-1 plan. On 08/08/2025 he exercised options with an exercise price of $6.93 to acquire 10,231 shares and sold portions of those shares: 3,110 sold at a weighted-average price of $19.44 (sales ranged $19.375–$19.46) and 7,121 sold at a weighted-average price of $19.696 (sales ranged $19.48–$20.46). The sales were effected pursuant to a 10b5-1 trading plan adopted March 14, 2024.

Additional details: the exercised options include a 2015 grant that is fully vested and exercisable through its expiration on August 13, 2025. The filing notes remaining options to purchase 10,231 shares referenced in Table II and additional options to purchase up to an aggregate of 101,820 shares. The Form 4 was filed with a signature dated 08/12/2025 by an attorney-in-fact.

Insights

Securities Analyst

TL;DR: Director exercised options and sold acquired shares under a pre-established 10b5-1 plan; transaction sizes and prices are disclosed.

The filing shows an orderly exercise of options and contemporaneous sales on 08/08/2025. Specifically, 10,231 shares were acquired via option exercise at an exercise price of $6.93. Portions of those shares were sold under the 10b5-1 plan: 3,110 shares at a weighted-average price of $19.44 and 7,121 shares at a weighted-average price of $19.696. Sales occurred across price ranges disclosed in the filing. The disclosure is clear on quantities, price ranges, and plan adoption date; no additional financial performance metrics are provided.

Corporate Governance Expert

TL;DR: Use of a 10b5-1 trading plan is documented; the filing discloses exercised options, sales, expiration, and remaining option holdings.

The report indicates the reporting person adopted a Rule 10b5-1 plan on March 14, 2024 to facilitate exercise and sale of options expiring August 13, 2025. The exercised option lot from a 2015 grant is fully vested and was exercised for 10,231 shares. The filing also discloses additional option rights of up to 101,820 shares. The Form 4 provides the necessary compliance information: transaction dates, exercise price, weighted-average sale prices, and the plan reference. No material unreported arrangements or unexplained discrepancies appear in the disclosed text.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RENTON HOLLINGS

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		M		10,231	A	$6.93	15,196	D
Common Stock	08/08/2025		S(1)		3,110	D	$19.44(2)	12,086	D
Common Stock	08/08/2025		S(1)		7,121	D	$19.696(3)	4,965	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock	$6.93	08/08/2025		M			10,231	(4)	08/13/2025	Common Stock	10,231	$0	0(5)	D

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options, including the options exercised and sold under this Form 4, which have an expiration date of August 13, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.375 to $19.46 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.48 to $20.46 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The stock option grant was issued on August 14, 2015, is fully vested and exercisable until its expiration date of August 13, 2025.

5. In addition to the remaining options to purchase 10,231 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 101,820 shares of common stock, which options vest according to their terms.

	/s/ Eric Loumeau, Attorney-in-Fact	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the ANAB Form 4 filed by Renton Hollings report?

The Form 4 reports that on 08/08/2025 Renton Hollings exercised options to acquire 10,231 shares at an exercise price of $6.93 and sold portions of those shares under a 10b5-1 plan.

Were the sales by the ANAB director part of a pre-established trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2024.

At what prices were the ANAB shares sold according to the filing?

The filing discloses weighted-average prices of $19.44 for 3,110 shares (price range $19.375–$19.46) and $19.696 for 7,121 shares (price range $19.48–$20.46).

Do the filings disclose any remaining option holdings for the reporting person?

Yes. In addition to the options exercised in this filing, the reporting person holds options to purchase 10,231 shares referenced in Table II and additional options to purchase up to an aggregate of 101,820 shares.

When do the exercised options expire?

The filing states the relevant option grant is fully vested and exercisable until its expiration date of August 13, 2025.